154 related articles for article (PubMed ID: 29454708)
1. Incidence and Risk of Oxaliplatin-Induced Hypersensitivity in Patients with Asymptomatic Prior Exposure: A Prospective Observational Study.
Sohn KH; Kang DY; Kim JY; Lee SY; Lee KH; Han SW; Kang HR
J Allergy Clin Immunol Pract; 2018; 6(5):1642-1648.e2. PubMed ID: 29454708
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity to oxaliplatin: clinical features and risk factors.
Parel M; Ranchon F; Nosbaum A; You B; Vantard N; Schwiertz V; Gourc C; Gauthier N; Guedat MG; He S; Kiouris E; Alloux C; Vial T; Trillet-Lenoir V; Freyer G; Berard F; Rioufol C
BMC Pharmacol Toxicol; 2014 Jan; 15():1. PubMed ID: 24417770
[TBL] [Abstract][Full Text] [Related]
4. Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.
Li M; Jiang C; Yang JW; Yu ZQ; Li W; Zhao L; Song QY; Zhang CL; Liu D
Curr Med Sci; 2021 Aug; 41(4):827-831. PubMed ID: 34403109
[TBL] [Abstract][Full Text] [Related]
5. Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure.
Lee SY; Kang HR; Song WJ; Lee KH; Han SW; Cho SH
Cancer Chemother Pharmacol; 2014 May; 73(5):1021-9. PubMed ID: 24696124
[TBL] [Abstract][Full Text] [Related]
6. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
[TBL] [Abstract][Full Text] [Related]
7. Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients.
Shen Y; Li C; Liu W; Mao W; Qian H; Wang H; Xu Q
Oncol Res; 2018 Jun; 26(5):801-807. PubMed ID: 29295722
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-induced hypersensitivity reactions: risk factors and management.
Selcuk A; Yıldız B
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2640-2645. PubMed ID: 37013782
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin: Detection and Management of Hypersensitivity Reactions.
Rogers BB; Cuddahy T; Briscella C; Ross N; Olszanski AJ; Denlinger CS
Clin J Oncol Nurs; 2019 Feb; 23(1):68-75. PubMed ID: 30682002
[TBL] [Abstract][Full Text] [Related]
10. Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study.
Palapinyo S; Klaewsongkram J; Sriuranpong V; Areepium N
Pharm Pract (Granada); 2022; 20(2):2635. PubMed ID: 35919789
[TBL] [Abstract][Full Text] [Related]
11. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy.
Wang AL; Patil SU; Long AA; Banerji A
Ann Allergy Asthma Immunol; 2015 Nov; 115(5):422-8. PubMed ID: 26298407
[TBL] [Abstract][Full Text] [Related]
12. Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity.
Alonso Martinez S; Segal NH; Cercek A; Yaeger R; Stadler Z; Kemeny NE; Nusrat M; Shahrokni A; Connell L; Saltz LB
Clin Colorectal Cancer; 2022 Jun; 21(2):149-153. PubMed ID: 35125319
[TBL] [Abstract][Full Text] [Related]
13. HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin.
Morgan R; Parsad S; Turaga KK; Eng OS
Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):551-553. PubMed ID: 32623784
[TBL] [Abstract][Full Text] [Related]
14. Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System.
Blumenthal KG; Lai KH; Huang M; Wallace ZS; Wickner PG; Zhou L
J Allergy Clin Immunol Pract; 2017; 5(3):737-743.e3. PubMed ID: 28110055
[TBL] [Abstract][Full Text] [Related]
15. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity Reaction.
Stein S; Dooley K; Ubohla NV; Hochster HS
Oncology (Williston Park); 2022 Jul; 36(7):414-419. PubMed ID: 35849782
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity reactions associated with oxaliplatin.
Saif MW
Expert Opin Drug Saf; 2006 Sep; 5(5):687-94. PubMed ID: 16907658
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
Park SJ; Lee KY; Park WS; Min SY
Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
[TBL] [Abstract][Full Text] [Related]
19. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
[TBL] [Abstract][Full Text] [Related]
20. Drug Hypersensitivity Reactions Documented in Electronic Health Records within a Large Health System.
Wong A; Seger DL; Lai KH; Goss FR; Blumenthal KG; Zhou L
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1253-1260.e3. PubMed ID: 30513361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
